O3 Developing a pharmacist prescribing role within child and adolescent mental health services (CAMHS)
Authors: O’Brien Claire 
Published: June 2019

Aim

CAMHS were unable to achieve the waiting time target for the Attention Deficit Hyperactivity Disorder (ADHD) titration clinic due to ongoing medical staff vacancies. Patients were waiting up to 7 months after diagnosis to commence medication which has a significant impact on quality of life and education.1 The aim of this project was to utilise the skills of a pharmacist independent prescriber to initiate medication and review the response and to evaluate the impact on waiting times.

Methods

Following funding approval, resource was made available to release an independent prescribing pharmacist for 1.5 days a week. Over a period of 8 weeks the following training was undertaken: shadowing clinics; reading books; national and local guidelines; accessing IT systems eg, TrakCare, EMIS, Winscribe; measuring height, weight and blood pressure; attending training sessions; appointing patients to the pharmacist led clinic from January 2018. The patient attends a baseline appointment where ADHD symptoms are assessed and medication options are discussed. The most appropriate medication is initiated at the lowest dose and is reviewed and adjusted at appointments every 2 weeks. On average it takes 4–5 appointments to complete a titration and stabilise the patient on a regular dose. Upon completion of the medication titration, a request is sent to the GP to commence repeat prescribing as per the local protocol. The patient is then appointed to the specialist nurse 3 month review clinic list.

Results

Following a review and update of the ADHD titration waiting list, there were 78 patients to be initiated on medication with new patients being added each week following their end of assessment diagnosis. Over the last 6 months, the pharmacist has titrated 28 patients (36%) onto ADHD medication. 3 patients did not respond to the first line stimulant and 1 patient has not responded to the first or second line stimulant and is currently being titrated onto a non-stimulant option. All patients on the list have been appointed to a clinic run by a non-medical prescriber or a nurse with support from a medical prescriber. Moving forward, the new pathway allows newly diagnosed patients to start medication either at their diagnosis appointment or given an appointment with the pharmacist for the following week. This may result in no waiting list at all. The service has also benefitted from having a pharmacist available every week to discuss issues with clinical governance processes and high risk medication.

Conclusion

The pharmacist independent prescriber played a significant role in the reduction of the waiting list for initiation of medication to treat ADHD. Due to the number of titrations completed within the last 6 months, there is now pressure on the 3 month review waiting list. By continuing to utilise the pharmacist independent prescriber to initiate and titrate medication, this will free up specialist nurse time to focus on initial assessments and the review clinics. As a result, the clinical group are planning to provide permanent funding for this role to continue to support the new model of ADHD clinic.

Reference

National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. London: NICE [NG87] March 2018